315 results Stibbe advises Clayton Dubilier & Rice LLC Stibbe advised private equity firm Clayton Dubilier & Rice LLC on the dual-track exit process of Mauser Group N.V., a global producer of industrial packaging. Stibbe represents Simed in dispute with Slotervaart hospital Stibbe represented Simed International in a dispute with the privately-owned Slotervaart hospital in Amsterdam. The Slotervaart hospital claimed that Simed International had sent incorrect invoices to the Slotervaart hospital, which would therefore have b Stibbe advises Expedia on the IPO of trivago Expedia is one of the world’s leading travel companies, with an extensive brand portfolio that includes some of the world’s most trusted online travel brands, including trivago. Stibbe advises on the IPO of Yandex Stibbe advises client in the pharmaceutical sector Stibbe assisted a client in the pharmaceutical sector with conducting an in-depth legal assessment regarding the scope and modalities of the safety features to be added to (the packaging of) medicinal products. Stibbe advises Syngenta Stibbe assisted Syngenta Crop Protection AG in its successful public voluntary take-over bid on all outstanding securities of Devgen NV. Stibbe advises on the IPO of Ziggo Stibbe advises Forbion Capital Partners Advising Forbion Capital Partners on the delisting of Amsterdam Molecular Therapeutics (AMT) Holding. Stibbe advises ING Advising the Dutch financial group ING in selling its stake in US bank Capital One for USD 3 billion. Stibbe advises leading plasma protein biotherapeutics company Stibbe advised a plasma protein biotherapeutics company on Belgium's implementation of a new Act on public procurement law that obliges Belgian hospitals to conduct a public procurement process for public contracts for the supply of medicinal products. Stibbe advises leading Belgian bank Stibbe assisted a leading Belgian bank with a number of highly complex and sensitive litigation cases about the sale of Collateralized Debt Obligations (CDOs) to corporate and private clients during the period 2005-2007. Stibbe advises on the contemplated IPO of Agendia Stibbe advises biotech company Stibbe advised a leading biotechnology company on the legal aspects of clinical trials development for biotech medicinal products. Stibbe advises major pharmaceutical company Stibbe assisted a global innovative pharmaceutical company in a complex co-marketing and co-promotion agreement and advised it on the impact of an innovative product’s registration at the European Medicines Agency. Stibbe advises on the IPO of Tornier Stibbe advises Cellerix Stibbe assisted Cellerix with its merger with Euronext-Brussels-listed Tigenix. Elvis Musema Junior Associate Brussels Vince Van der Wangen Associate Brussels Pagination Previous page Page 15 Page 16 Current page 17 Page 18 Next page
Stibbe advises Clayton Dubilier & Rice LLC Stibbe advised private equity firm Clayton Dubilier & Rice LLC on the dual-track exit process of Mauser Group N.V., a global producer of industrial packaging.
Stibbe represents Simed in dispute with Slotervaart hospital Stibbe represented Simed International in a dispute with the privately-owned Slotervaart hospital in Amsterdam. The Slotervaart hospital claimed that Simed International had sent incorrect invoices to the Slotervaart hospital, which would therefore have b
Stibbe advises Expedia on the IPO of trivago Expedia is one of the world’s leading travel companies, with an extensive brand portfolio that includes some of the world’s most trusted online travel brands, including trivago.
Stibbe advises client in the pharmaceutical sector Stibbe assisted a client in the pharmaceutical sector with conducting an in-depth legal assessment regarding the scope and modalities of the safety features to be added to (the packaging of) medicinal products.
Stibbe advises Syngenta Stibbe assisted Syngenta Crop Protection AG in its successful public voluntary take-over bid on all outstanding securities of Devgen NV.
Stibbe advises Forbion Capital Partners Advising Forbion Capital Partners on the delisting of Amsterdam Molecular Therapeutics (AMT) Holding.
Stibbe advises ING Advising the Dutch financial group ING in selling its stake in US bank Capital One for USD 3 billion.
Stibbe advises leading plasma protein biotherapeutics company Stibbe advised a plasma protein biotherapeutics company on Belgium's implementation of a new Act on public procurement law that obliges Belgian hospitals to conduct a public procurement process for public contracts for the supply of medicinal products.
Stibbe advises leading Belgian bank Stibbe assisted a leading Belgian bank with a number of highly complex and sensitive litigation cases about the sale of Collateralized Debt Obligations (CDOs) to corporate and private clients during the period 2005-2007.
Stibbe advises biotech company Stibbe advised a leading biotechnology company on the legal aspects of clinical trials development for biotech medicinal products.
Stibbe advises major pharmaceutical company Stibbe assisted a global innovative pharmaceutical company in a complex co-marketing and co-promotion agreement and advised it on the impact of an innovative product’s registration at the European Medicines Agency.
Stibbe advises Cellerix Stibbe assisted Cellerix with its merger with Euronext-Brussels-listed Tigenix.